Skip to content
Medical Health Aged Care

MINISTER WELLS WELCOMED TO A WARM VISIT AND TOUR OF NEWDIRECTION CARE MICROTOWN

NewDirection Care - Media Release 2 mins read

NewDirection Care welcomed the Minister for Aged Care and Sport the Hon Anika Wells to their MICRO TOWN® community in Bellmere last week.

 

The first of its kind in Australia, MICRO TOWN® is an aged care model resembling a typical suburban community equipped with a grocery store, community centre, hairdressers, and much more.  

 

“The residents and our team were delighted to have the opportunity to interact with Minister Wells and to showcase our community and explain why our model is so different to every other residential aged care,” said Natasha Chadwick, Founder and Managing Director of NewDirection Care.

 

“The Minister’s visit was an important recognition of the necessity of our service. We deeply appreciate the Government’s continued commitment to improve Australia’s aged care system.

 

“With more and more Australian’s opting out of ‘traditional’ aged care, older Australians deserve innovative models that meet their growing needs and expectations.”

 

Underpinned by all fundamental mechanisms of quality care, the MICRO TOWN® provides residents a true home within the larger MICRO TOWN® village, supporting each resident to maintain independence and choice in their life.

 

“Here at Bellmere, we offer holistic care that not only meticulously attends to each residents’ physical needs, but also their social, mental, and spiritual wellbeing.

 

“Life is about more than care and clinical outcomes. At NewDirection Care we focus on providing positive experiences and quality of life as residents age.

 

“For Minister Wells to witness first-hand the difference of our MICRO TOWN® was an incredible opportunity and an honour.”

 

“The chat with the Minister was really friendly and personal,” said Zara, a team member who works as a House Companion™ Liaison Nurse [enrolled nurse].

 

“It was the close-knit family at the MICRO TOWN® that drew me to NewDirection Care. I can really build relationships with the residents.”

 

Judy, a resident who spoke with the Minister, said: “She was so easy to talk to. She asked me questions like am I enjoying myself?”

 

“Of course, the answer was yes. It’s fantastic here. I’ve been through medicalised care and it can be very isolating.

 

“I’m so happy my daughter did the research and found NewDirection Care.”

 

Since 2017, NewDirection Care has provided freedom and choice to older Australians with a model that protects the dignity of every individual, no matter their diagnosis or support need.

 

“Innovation is the future of aged care. It’s what older and vulnerable Australians want and its what our care system needs.”

 

MEDIA CONTACT: 0474 697 235

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.